Spero Therapeutics (2HA) Ratios
Spero Therapeutics Ratios
DE:2HA's free cash flow for Q2 2026 was $-5.36M. For the 2026 fiscal year, DE:2HA's free cash flow was increased by $0.00 and operating cash flow was $-5.36M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.59 | 2.19 | 3.53 | 5.04 | 8.46 |
| Quick Ratio | 7.59 | 2.19 | 3.53 | 5.25 | 8.46 |
| Cash Ratio | 4.54 | 1.08 | 2.05 | 5.04 | 6.03 |
| Solvency Ratio | 0.87 | -1.06 | 0.31 | -0.93 | -1.08 |
| Operating Cash Flow Ratio | -1.42 | -0.48 | -0.89 | -0.36 | -3.45 |
| Short-Term Operating Cash Flow Coverage | -6.45 | -13.43 | -19.21 | 0.00 | 0.00 |
| Net Current Asset Value | $ 57.39M | $ 42.86M | $ 55.71M | $ 60.24M | $ 75.09M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.04 | 0.03 | 0.05 | 0.04 |
| Debt-to-Equity Ratio | 0.05 | 0.09 | 0.05 | 0.09 | 0.08 |
| Debt-to-Capital Ratio | 0.05 | 0.09 | 0.05 | 0.08 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.17 | 2.40 | 1.71 | 1.64 | 1.94 |
| Debt Service Coverage Ratio | 4.38 | -41.51 | 14.29 | -16.48 | -44.93 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -16.20 | -45.35 |
| Debt to Market Cap | 0.01 | 0.03 | 0.02 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.08 | 0.11 | 0.25 | 0.30 |
| Net Debt to EBITDA | -4.23 | 0.67 | -2.61 | 2.39 | 1.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | -101.67% | 50.43% | 100.00% | 100.00% |
| EBIT Margin | 14.82% | -151.08% | 25.81% | -90.18% | -2860.46% |
| EBITDA Margin | 14.82% | -151.08% | 26.16% | -88.39% | -2839.41% |
| Operating Profit Margin | -0.04% | -152.91% | 20.70% | -86.86% | -2865.50% |
| Pretax Profit Margin | 14.82% | -142.91% | 24.48% | -95.55% | -2923.65% |
| Net Profit Margin | 14.38% | -142.91% | 21.98% | -95.55% | -2923.65% |
| Continuous Operations Profit Margin | 14.38% | -142.91% | 21.98% | -95.55% | -2923.65% |
| Net Income Per EBT | 97.05% | 100.00% | 89.77% | 100.00% | 100.00% |
| EBT Per EBIT | -36804.17% | 93.46% | 118.26% | 110.00% | 102.03% |
| Return on Assets (ROA) | 12.44% | -62.03% | 12.50% | -37.19% | -52.47% |
| Return on Equity (ROE) | 14.52% | -148.66% | 21.34% | -61.13% | -101.66% |
| Return on Capital Employed (ROCE) | -0.04% | -119.35% | 14.79% | -40.91% | -57.72% |
| Return on Invested Capital (ROIC) | -0.04% | -116.05% | 13.12% | -40.25% | -57.21% |
| Return on Tangible Assets | 12.44% | -62.03% | 12.50% | -37.19% | -52.47% |
| Earnings Yield | 6.57% | -123.19% | 29.44% | -71.38% | -18.15% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.35 | 0.91 | 2.05 | 44.81 | 1.16 |
| Payables Turnover | 0.00 | 13.24 | 37.33 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 40.28 | 15.41 | 24.97 | 8.85 | 0.41 |
| Asset Turnover | 0.87 | 0.43 | 0.57 | 0.39 | 0.02 |
| Working Capital Turnover Ratio | 1.02 | 0.63 | 1.14 | 0.43 | 0.02 |
| Cash Conversion Cycle | 155.42 | 371.67 | 168.52 | 8.14 | 314.00 |
| Days of Sales Outstanding | 155.42 | 399.23 | 178.30 | 8.14 | 314.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 27.56 | 9.78 | 0.00 | 0.00 |
| Operating Cycle | 155.42 | 399.23 | 178.30 | 8.14 | 314.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.23 | -0.43 | -0.63 | -0.21 | -2.08 |
| Free Cash Flow Per Share | -0.23 | -0.43 | -0.63 | -0.21 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 |
| Operating Cash Flow Coverage Ratio | -4.36 | -5.46 | -5.95 | -1.16 | -8.77 |
| Operating Cash Flow to Sales Ratio | -0.21 | -0.49 | -0.32 | -0.16 | -20.96 |
| Free Cash Flow Yield | -9.67% | -42.12% | -42.59% | -11.89% | 0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 15.53 | -0.81 | 3.40 | -1.40 | -5.51 |
| Price-to-Sales (P/S) Ratio | 2.19 | 1.16 | 0.75 | 1.34 | 161.12 |
| Price-to-Book (P/B) Ratio | 2.21 | 1.21 | 0.72 | 0.86 | 5.60 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.34 | -2.37 | -2.35 | -8.41 | 0.00 |
| Price-to-Operating Cash Flow Ratio | -10.34 | -2.37 | -2.35 | -8.41 | -7.69 |
| Price-to-Earnings Growth (PEG) Ratio | -0.14 | 0.00 | -0.03 | 0.02 | 0.32 |
| Enterprise Value Multiple | 10.55 | -0.10 | 0.25 | 0.87 | -4.47 |
| Enterprise Value | 93.16M | 7.07M | 6.68M | -37.44M | 389.39M |
| EV to EBITDA | 10.55 | -0.10 | 0.25 | 0.87 | -4.47 |
| EV to Sales | 1.56 | 0.15 | 0.06 | -0.77 | 126.84 |
| EV to Free Cash Flow | -7.38 | -0.30 | -0.20 | 4.84 | 0.00 |
| EV to Operating Cash Flow | -7.38 | -0.30 | -0.20 | 4.84 | -6.05 |
| Tangible Book Value Per Share | 1.05 | 0.85 | 2.03 | 2.02 | 2.86 |
| Shareholders’ Equity Per Share | 1.05 | 0.85 | 2.03 | 2.02 | 2.86 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | 0.00 | 0.10 | 0.00 | 0.00 |
| Revenue Per Share | 1.06 | 0.89 | 1.97 | 1.29 | 0.10 |
| Net Income Per Share | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 |
| Tax Burden | 0.97 | 1.00 | 0.90 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.95 | 0.95 | 1.06 | 1.02 |
| Research & Development to Revenue | 0.65 | 2.02 | 0.50 | 0.98 | 21.02 |
| SG&A to Revenue | 0.36 | 0.49 | 0.24 | 0.75 | 13.58 |
| Stock-Based Compensation to Revenue | 0.07 | 0.16 | 0.08 | 0.00 | 0.00 |
| Income Quality | -1.47 | 0.34 | -1.45 | 0.17 | 0.72 |
Currency in USD
